BocNHNHCO(CH2)5NH2 | 848083-90-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: BocNHNHCO(CH2)5NH2
• 英文别名: 6-amino-N-[(tert-butoxy)carbonylamino]-hexanamide；6-amino-N-[(tert-butoxy)carbonylamino]hexanamide；tert-butyl N-(6-aminohexanoylamino)carbamate
• CAS: 848083-90-9
• 化学式: C₁₁H₂₃N₃O₃
• 分子量: 245.322
• InChiKey: RJQKOJIXLGCWSP-UHFFFAOYSA-N

物化性质

• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  BocNHNHCO(CH2)5NH2 在 N-羟基-7-氮杂苯并三氮唑 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N,N'-二异丙基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 2-[(E)-[[5-[[6-(2-dodecanoylhydrazinyl)-6-oxohexyl]carbamoyl]pyridin-2-yl]hydrazinylidene]methyl]benzenesulfonic acid
  参考文献：
  名称：

  [EN] COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE
  [FR] COMPOSES CONTENANT DES SUBSTRATS DE METALLOPROTEINASE MATRICIELLE ET PROCEDES D'UTILISATION ASSOCIES

  摘要：

  揭示了用于诊断剂的化合物，用于检测、成像和/或监测患者感兴趣部位处与基质金属蛋白酶活性相关的病理紊乱。还揭示了含有这些化合物的组合物和试剂盒。此外，还揭示了检测、成像和/或监测患者体内基质金属蛋白酶或与基质金属蛋白酶活性相关的病理紊乱存在的方法。

  公开号：

  WO2005023314A1
• 作为产物：
  描述：

  肼基甲酸叔丁酯 在 哌啶 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.66h， 生成 BocNHNHCO(CH2)5NH2
  参考文献：
  名称：

  [EN] COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE
  [FR] COMPOSES CONTENANT DES SUBSTRATS DE METALLOPROTEINASE MATRICIELLE ET PROCEDES D'UTILISATION ASSOCIES

  摘要：

  揭示了用于诊断剂的化合物，用于检测、成像和/或监测患者感兴趣部位处与基质金属蛋白酶活性相关的病理紊乱。还揭示了含有这些化合物的组合物和试剂盒。此外，还揭示了检测、成像和/或监测患者体内基质金属蛋白酶或与基质金属蛋白酶活性相关的病理紊乱存在的方法。

  公开号：

  WO2005023314A1

文献信息

• Compounds containing matrix metalloproteinase substrates and methods of their use
  申请人：Harris D. Thomas

  公开号：US20050106100A1

  公开（公告）日：2005-05-19

  Compounds for use in a diagnostic agent for detecting, imaging, and/or monitoring a pathological disorder associated with matrix metalloproteinase activity at a site of interest in a patient are disclosed. Compositions and kits containing the compounds are also disclosed. In addition, methods of detecting, imaging, and/or monitoring the presence of matrix metalloproteinase or a pathological disorder associated with matrix metalloprotainase activity in a patient are disclosed.

  本文介绍了用于诊断检测、成像和/或监测患者体内与基质金属蛋白酶活性相关的病理性疾病的化合物。还公开了含有这些化合物的组合物和试剂盒。此外，还公开了检测、成像和/或监测患者体内基质金属蛋白酶或与基质金属蛋白酶活性相关的病理性疾病存在的方法。
• Hydrazide conjugates as imaging agents
  申请人：Harris D. Thomas

  公开号：US20070014721A1

  公开（公告）日：2007-01-18

  The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the arterial wall. In addition, the disclosure is directed to methods of detecting and/or imaging and/or monitoring changes in the arterial wall, including expansive and constrictive remodeling, total vessel wall area, internal lumen size, and exterior artery perimeter.

  本公开涉及诊断试剂。更具体地说，本公开涉及用于检测和/或成像和/或监测与冠状动脉斑块、颈动脉斑块、主动脉斑块、动脉血管斑块、动脉瘤、血管炎和其他动脉壁疾病相关的病理障碍的化合物、诊断试剂、组合物和试剂盒。此外，本公开还涉及检测和/或成像和/或监测动脉壁变化的方法，包括扩张性和收缩性重塑、总血管壁面积、内腔大小和外动脉周长。
• WO2007/5491
  申请人：——

  公开号：——

  公开（公告）日：——
• Site-specific conjugation of metal carbonyl dendrimer to antibody and its use as detection reagent in immunoassay
  作者：Nathalie Fischer-Durand、Michèle Salmain、Bogna Rudolf、Lili Dai、Lauriane Jugé、Vincent Guérineau、Olivier Laprévote、Anne Vessières、Gérard Jaouen

  DOI：10.1016/j.ab.2010.08.027

  日期：2010.12

  We describe here the conjugation of polyclonal goat anti-rabbit antibody to generation 4 polyamidoamine (G4-PAMAM) dendrimers carrying (i) (eta(5)-cyclopentadienyl) iron dicarbonyl succinimidato complexes as infrared (IR) probes, (ii) nitroaniline entities as nuclear magnetic resonance (NMR) probes, (iii) acetamide groups for surface neutralization, and (iv) hydrazide-terminated spacer arms for the reaction with aldehyde. To preserve a high binding affinity, the conjugation was performed on the carbohydrate moieties located on the Fc fragment. The resulting conjugates were characterized by Fourier transform-IR, ultraviolet (UV), and high-mass matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. On the basis of relative concentration ratios of IR probes and antibody, an average labeling of 30 IR probes per antibody was reached (i.e., more than twice the value obtained with our previous strategy that generated no spacer arm). Immunoassays revealed that the antibody-dendrimer conjugates retained 55.1% of immunoreactivity on average with respect to underivatized antibody. Finally, the conjugates were used to quantify their antigen by solid-phase carbonyl metallo immunoassay (CMIA). Results showed a significant enhancement of the IR signal, demonstrating the efficiency of the new conjugation strategy and the potential of the new antibody-dendrimer conjugates as universal immunoanalytical reagents. (C) 2010 Elsevier Inc. All rights reserved.
• EP1691845A4
  申请人：——

  公开号：EP1691845A4

  公开（公告）日：2009-02-25